by Madaline Spencer | Aug 17, 2026
Ajay K. Nooka, MD, MPH, FACP, Director of the Myeloma Program at the Emory University School of Medicine, discusses topline results from the MonumenTAL-6 clinical trial testing Tecvayli (teclistamab) in adults with relapsed/refractory multiple myeloma (RRMM). ...
by Madaline Spencer | Aug 14, 2026
Alexandra Miller, MD, PhD, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at the Perlmutter Cancer Center at NYU Langone Health, discusses follow-up data on the safety and efficacy of safusidenib in patients with IDH-mutant gliomas....
by Madaline Spencer | Aug 12, 2026
Guy Young, MD, Director of the Hemostasis and Thrombosis Program at Children’s Hospital Los Angeles, discusses an ATLAS-OLE subgroup analysis of fitusiran in patients with hemophilia. Hemophilia is a rare bleeding disorder that slows the blood...
by Madaline Spencer | Aug 10, 2026
Priya Kishnani, MD, Professor and Chief of the Division of Medical Genetics at Duke University, discusses the GALILEO-3 clinical trial of FLT201 in adults with Gaucher disease type 1 (GD1). GD1 is the most common form of Gaucher disease. It is caused by...
by Madaline Spencer | Aug 7, 2026
The US Food and Drug Administration (FDA) has approved Orzeyful (oveporexton) for the treatment of adults with narcolepsy type 1 Narcolepsy is a chronic neurological disorder characterized by an inability of the brain to control sleep-wake cycles. Patients with...
